Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 9,700 Shares

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 9,700 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00. Following the completion of the sale, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,947,181.84. The trade was a 15.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Price Performance

NASDAQ:IRON traded up $0.02 on Wednesday, hitting $70.47. The company had a trading volume of 1,220,498 shares, compared to its average volume of 485,366. The stock has a market capitalization of $2.69 billion, a price-to-earnings ratio of -10.64 and a beta of 0.93. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $68.80 and a two-hundred day moving average of $71.18. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, research analysts anticipate that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IRON shares. Truist Financial lowered their target price on Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a report on Friday, February 27th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Morgan Stanley boosted their price target on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Wedbush reaffirmed an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $105.80.

Institutional Trading of Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after buying an additional 828,248 shares during the period. BVF Inc. IL bought a new stake in shares of Disc Medicine in the 4th quarter valued at about $51,616,000. Jennison Associates LLC acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $42,252,000. Perceptive Advisors LLC bought a new position in shares of Disc Medicine during the fourth quarter worth about $35,794,000. Finally, RA Capital Management L.P. raised its position in shares of Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after acquiring an additional 399,026 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.